REPLIMUNE GROUP INC (REPL)

US76029N1063 - Common Stock

11.64  +0.29 (+2.56%)

Fundamental Rating

2

Overall REPL gets a fundamental rating of 2 out of 10. We evaluated REPL against 568 industry peers in the Biotechnology industry. While REPL seems to be doing ok healthwise, there are quite some concerns on its profitability. REPL is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

REPL had negative earnings in the past year.
REPL had a negative operating cash flow in the past year.
In the past 5 years REPL always reported negative net income.
In the past 5 years REPL always reported negative operating cash flow.

1.2 Ratios

REPL has a Return On Assets of -41.13%. This is comparable to the rest of the industry: REPL outperforms 55.77% of its industry peers.
With a decent Return On Equity value of -51.59%, REPL is doing good in the industry, outperforming 65.72% of the companies in the same industry.
Industry RankSector Rank
ROA -41.13%
ROE -51.59%
ROIC N/A
ROA(3y)-32.26%
ROA(5y)-26.83%
ROE(3y)-39.24%
ROE(5y)-32.52%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for REPL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

REPL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, REPL has more shares outstanding
The debt/assets ratio for REPL is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 1.85 indicates that REPL is not a great score, but indicates only limited risk for bankruptcy at the moment.
REPL's Altman-Z score of 1.85 is fine compared to the rest of the industry. REPL outperforms 69.80% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that REPL is not too dependend on debt financing.
The Debt to Equity ratio of REPL (0.16) is worse than 66.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 1.85
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 13.46 indicates that REPL has no problem at all paying its short term obligations.
REPL has a better Current ratio (13.46) than 86.32% of its industry peers.
REPL has a Quick Ratio of 13.46. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.46, REPL belongs to the top of the industry, outperforming 86.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.46
Quick Ratio 13.46

1

3. Growth

3.1 Past

REPL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.10%.
EPS 1Y (TTM)-10.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.58% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.18%
EPS Next 2Y6.11%
EPS Next 3Y11.31%
EPS Next 5Y14.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REPL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REPL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.11%
EPS Next 3Y11.31%

0

5. Dividend

5.1 Amount

No dividends for REPL!.
Industry RankSector Rank
Dividend Yield N/A

REPLIMUNE GROUP INC

NASDAQ:REPL (10/22/2024, 1:28:38 PM)

11.64

+0.29 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap795.24M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.13%
ROE -51.59%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 13.46
Quick Ratio 13.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-10.1%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y2.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y